Mylan N.V. (NASDAQ: MYL) is scheduled to report its third-quarter financial results after the markets close on Wednesday. The consensus estimates from Thomson Reuters are $1.46 in earnings per share (EPS) and $3.12 billion in revenue. In the same period of last year, Mylan posted EPS of $1.43 and $2.71 billion in revenue.
Within the past month, Mylan reached an agreement with the U.S. Department of Justice to pay $465 million to resolve questions about the classification of it EpiPen auto-injector products for purposes of the Medicaid drug rebate program.
At that time, the company has reduced its full fiscal 2016 adjusted earnings per share (EPS) guidance from a prior range of $4.85 to $5.15 to a new range of $4.70 to $4.90. Mylan attributed the majority of the change to “previously announced changes in EpiPen Auto-Injector access programs and the upcoming launch of the generic to EpiPen Auto-Injector.”
Mylan also said the settlement terms “provide for resolution of all potential rebate liability claims by federal and state governments as to whether the product should have been classified as an innovator drug for [Centers for Medicaid and Medicare Services] CMS purposes and subject to a higher rebate formula.”
A few analysts weighed in on Mylan ahead of the earnings report:
- Mizuho has a Buy rating with a $49 price target.
- JPMorgan has a Buy rating with a $52 price target.
- BTIG Research reiterated a Buy rating with a $55 price target.
- RBC Capital Markets reiterated a Sector Perform rating with a $48 price target.
- Leerink Swann has a Buy rating with a $45 price target.
- Wells Fargo has a Hold rating with a $44 price target.
- Argus has a Buy rating with a $55 price target.
Excluding Wednesday’s post-election move, Mylan has vastly underperformed the broad markets, with the stock down 31% year to date.
Shares of Mylan were trading up 5% at $39.07 on Wednesday, with a consensus analyst price target of $52.53 and a 52-week trading range of $33.60 to $55.51.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
